sarepta gene therapy - Search News

Sarepta, European Medicines Agency and gene therapy

Sarepta’s Duchenne Gene Therapy Placed on Hold in Europe Pending Death Investigation

The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US teenager, who suffered acute liver failure after receiving Elevidys, can be precisely determined.

Reuters on MSN · 16h

Sarepta halts three studies testing gene therapy for muscle disorder

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment. The company reported on March 18 that a 16-year-old boy died from acute liver failure months after receiving the U.

Fierce Pharma · 1d

UPDATE: After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in Europe of their Duchenne muscular dystrophy (DMD) gene therapy Elevidys.

Zacks Investment Research on MSN18h

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies ...

16hon MSN

Sarepta, Roche seek to resume Elevidys trials

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

17h

Sarepta Therapeutics Provides Update on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Multiple studies of Sarepta's DMD therapy halted after death

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

Pharmaceuticals are spared from tariffs, for now

President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...

1don MSN

Sarepta falls after clinical hold related to Elevidys trials

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy ...

16h

Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

BioPharma Dive1d

Roche halts testing of Sarepta Duchenne gene therapy in Europe

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...

1d

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results